A Phase I/II Trial of Ruxolitinib (Jakafi) in Patients With Chronic Lymphocytic Leukemia Who Are Unfit for Conventional First-line Therapy Due to Age or 17p Deletions
Phase of Trial: Phase I/II
Latest Information Update: 30 Sep 2016
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 23 Sep 2016 Status changed from recruiting to completed.
- 21 Apr 2014 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 26 Dec 2013 New trial record